Your browser doesn't support javascript.
loading
Is Regular Probiotic Practice Safe for Management of Sepsis? / 中国结合医学杂志
Chin. j. integr. med ; Chin. j. integr. med;(12): 185-192, 2022.
Article de En | WPRIM | ID: wpr-928935
Bibliothèque responsable: WPRO
ABSTRACT
For decades, the gut has been thought to play an important role in sepsis pathogenesis. Sepsis is a serious life-threatening, chronic condition of an infection caused by dysregulated host immune response in most of the intensive care unit patients. Probiotics have dual roles in polymicrobial sepsis i.e. probiotics may induce sepsis in many cases and may prevent its prognosis in many cases. Experimental evidence from both pre-clinical and clinical studies have demonstrated that probiotic therapy ameliorates various inflammatory mediators such as tumor necrosis factor, interleukin-10 (IL-10), IL-6, etc., in septicemia. In addition, probiotic use was also found to reduce the severity of pathological conditions associated with irritable bowel disorder and prevent development of endocarditis in septicemia. On contrary, probiotic therapy in neonatal and athymic adult mice fail to provide any beneficial effects on mortality and sepsis-induced inflammation. Importantly, in few clinical trials probiotic use was found to aggravate sepsis by promoting inflammatory cascade rather than suppressing it. This review discusses various studies regarding the beneficial or harmful effects associated with probiotic therapy in sepsis.
Sujet(s)
Mots clés
Texte intégral: 1 Indice: WPRIM Sujet Principal: Facteur de nécrose tumorale alpha / Sepsie / Probiotiques / Inflammation Type d'étude: Prognostic_studies Limites du sujet: Animals / Humans langue: En Texte intégral: Chin. j. integr. med Année: 2022 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Facteur de nécrose tumorale alpha / Sepsie / Probiotiques / Inflammation Type d'étude: Prognostic_studies Limites du sujet: Animals / Humans langue: En Texte intégral: Chin. j. integr. med Année: 2022 Type: Article